Media center

Meitar Represented PrimeSence, 3D sensing technology developer company, in its acquisition by a multinational corporation.

Meitar represented Conduit in its spin-off of ClientConnect, Conduit’s toolbar division, and the subsequent purchase of ClientConnect by Perion Network Ltd., a NASDAQ company, in an all stock transaction. Conduit’s shareholders and option holders received 81% of Perion shares in the transaction, which closed in January 2014.

Meitar represented NYSE-listed Covidien, a US medical device manufacture, in its acquisition of Given Imaging, a medical technology company that develops and manufactures the swallowable imaging capsules for endoscopy, for approximately $1 billion.

Meitar represented Israeli app deployment and management company Nolio in its acquisition by IT software giant CA Technologies.

Meitar represented Enzymotec Ltd., a developer of lipid-based products and solutions for the nutritional and healthcare markets, in its initial public offering on NASDAQ raising approximately $70M (including exercise at closing of the underwriters’ overallotment option in full). Bank of America Merrill Lynch and Jefferies LLC acted as joint book-running managers for the offering.

Meitar represented New York/London-based private equity firm Rhone Capital LLC in its acquisition of the European and Israeli operations of Eden Springs for approximately $90 million, based on an enterprise value of Euro 300 million.

Meitar represented Stratasys Ltd. (SSYS) in a public offering of ordinary shares for approximately $481M on NASDAQ with JP Morgan as sole-book-runner and Piper Jaffray, Morgan Stanley, Bank of America Merrill Lynch and Needham as co-managers.